Movement Alert|Legend Biotech Rises 5.25% in Regular Trading, Director Share Purchase Spurs Rebound

Market Focus11-18

On November 18, Legend Biotech rose 5.25% in Regular Trading, trading at $16.92 per share, with turnover of $3.4256 million.

The clearest catalyst behind the move was a newly disclosed insider purchase: director Peter Salovey acquired 20,000 ordinary shares for about $183,250, lifting his direct beneficial ownership to 75,096 shares.

The buying came after a volatile post-earnings stretch. Legend Biotech reported third-quarter net profit of $51.7 million, reversing a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million was slightly below market expectations, prompting a series of analyst target cuts and an Evercore ISI downgrade to In Line with a $20 price target. Against that backdrop, the director purchase appeared to improve near-term confidence and supported a technical rebound in the shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment